Fig. 1: Waterfall plots demonstrating the efficacy of belotecan and topotecan monotherapy in patients with sensitive-relapsed SCLC. | British Journal of Cancer

Fig. 1: Waterfall plots demonstrating the efficacy of belotecan and topotecan monotherapy in patients with sensitive-relapsed SCLC.

From: A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

Fig. 1

Maximum percentage changes in tumour size (sum of the longest diameters of target-lesions) from baseline, in topotecan (a) and belotecan (b) groups. Colours indicate best overall responses determined from the start of treatment until disease progression/recurrence. p values were obtained from Chi-square tests for comparisons of ORR and DCR between groups.

Back to article page